17.85 (-%)
As of Nov 12, 2024
Source:
We are a clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases. We utilize our proprietary oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens designed to achieve improved treatment outcomes. Our lead effort is to develop a functional cure for Chronic Hepatitis B (CHB), which often results in life-threatening conditions such as cirrhosis, end-stage liver disease (ESLD) and the most common form of liver cancer, hepatocellular carcinoma (HCC).
Country | United States |
Headquarters | south san francisco, california |
Phone Number | (800) 466-6059 |
Industry | manufacturing |
CEO | Lawrence M. Blatt, Ph.D. |
Website | www.aligos.com |